IP Library › Granted Patent US 12,359,264
Granted Patent B2
US 12,359,264 · App. 17/504,937 · Granted Jul 15, 2025

Co-binder assisted assay methods

Inventors: Eli N. Glezer (Del Mar, CA); George Sigal (Rockville, MD)
Assignee: Meso Scale Technologies, LLC.
C12Q1/70C12Q1/6813C12Q1/6834G01N33/542G01N33/54333
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,359,264
App. No.
17/504,937
Granted
Jul 15, 2025
Kind
B2
Abstract

The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays.

Claims (42)

1. A kit configured to conduct a binding assay for an analyte, the kit comprising:

(i) a solid surface comprising a first binding reagent immobilized thereto comprising a first binding region that binds to said analyte of interest, wherein said first binding reagent is linked to a first linking agent comprising a first oligonucleotide sequence;

(ii) a second binding reagent comprising a second binding region that binds to said analyte of interest, wherein said second binding reagent is linked to a second linking agent comprising a second oligonucleotide sequence, and

(iii) a bridging oligonucleotide comprising a sequence complementary to at least a portion of said first oligonucleotide sequence and said second oligonucleotide sequence,

wherein said second binding reagent is not immobilized to said solid surface,

wherein the bridging oligonucleotide or the second binding reagent comprises a detectable label.

2. A kit configured to conduct a binding assay for a plurality of analytes, the kit comprising:

(i) a solid surface including one or more first binding reagents immobilized thereto, wherein said one or more first binding reagents each comprise a first binding region that binds to one or more of said plurality of analytes and each of said one or more first binding reagents is linked to a first linking agent comprising a first oligonucleotide sequence;

(ii) one or more second binding reagents each comprising a second binding region that binds to one or more of said plurality of analytes, wherein each of said one or more second binding reagents is linked to a second linking agent comprising a second oligonucleotide sequence, and

(iii) one or more bridging oligonucleotides each comprising a sequence complementary to at least a portion of said first oligonucleotide sequence and said second oligonucleotide sequence,

wherein said one or more second binding reagents are not immobilized to said solid surface,

wherein the bridging oligonucleotide or the second binding reagent comprises a detectable label.

3. The kit of claim 1 , wherein said first binding region is specific for said analyte of interest.

4. The kit of claim 1 , wherein said second binding region is specific for said analyte of interest.

5. The kit of claim 1 , wherein said first binding reagent is an antibody.

6. The kit of claim 1 , wherein said second binding reagent is an antibody.

7. The kit of claim 2 , wherein said first binding region is specific for said one or more of said plurality of analytes.

8. The kit of claim 2 , wherein said second binding region is specific for said one or more of said plurality of analytes.

9. The kit of claim 2 , wherein said one or more first binding reagents are antibodies.

10. The kit of claim 2 , wherein said one or more second binding reagents are antibodies.

11. The kit of claim 1 , wherein said second binding reagent comprises a detectable label.

12. The kit of claim 2 , wherein said one or more second binding reagents comprise a detectable label.

13. The kit of claim 1 , wherein said first oligonucleotide sequence comprises about 5-15 bases.

14. The kit of claim 1 , wherein said second oligonucleotide sequence comprises about 5-15 bases.

15. The kit of claim 1 , wherein said first oligonucleotide sequence and said second oligonucleotide sequence each comprise a complementary binding sequence of about 4-8 bases in length which is complementary to the bridging oligonucleotide sequence.

16. The kit of claim 2 , wherein said first oligonucleotide sequence comprises about 5-15 bases.

17. The kit of claim 2 , wherein said second oligonucleotide sequence comprises about 5-15 bases.

18. The kit of claim 2 , wherein said first oligonucleotide sequence and said second oligonucleotide sequence each comprise a complementary binding sequence of about 4-8 bases in length which is complementary to the bridging oligonucleotide sequence.

19. The kit of claim 1 , wherein said first linking agent and/or said second linking agent further comprises a polymer unit.

20. The kit of claim 2 , wherein said first linking agent and/or said second linking agent further comprises a polymer unit.

21. The kit of claim 1 , wherein said bridging oligonucleotide comprises a detectable label.

22. The kit of claim 2 , wherein said one or more bridging oligonucleotides comprise a detectable label.

23. The kit of claim 1 , wherein said bridging oligonucleotide comprises about 5-20 bases.

24. The kit of claim 2 , wherein said one or more bridging oligonucleotides comprise about 5-20 bases.

25. The kit of claim 1 , wherein said solid surface is an electrode and said surface is configured for use in a measuring step comprising applying a voltage waveform to said electrode to generate electrochemiluminescence (ECL).

26. The kit of claim 2 , wherein said solid surface is an electrode and said surface is configured for use in a measuring step comprising applying a voltage waveform to said electrode to generate electrochemiluminescence (ECL).

27. The kit of claim 25 , wherein said bridging oligonucleotide comprises a detectable label, wherein said detectable label is an ECL label.

28. The kit of claim 26 , wherein said one or more bridging oligonucleotides comprise a detectable label, wherein said detectable label is an ECL label.

29. The kit of claim 27 , wherein said first and said second binding regions are specific for said analyte of interest, wherein said first and said second binging reagents are antibodies, wherein said first and said second oligonucleotide sequences each comprise about 5-15 bases, wherein said first and said second oligonucleotide sequences each comprise a complementary binding sequence of about 4-8 bases in length which is complementary to the bridging oligonucleotide sequence, and wherein said bridging oligonucleotide comprises about 5-20 bases.

30. The kit of claim 28 , wherein said first and said second binding regions are specific for one or more of said plurality of analytes, wherein said one or more first and said one or more second binging reagents are antibodies, wherein said first and said second oligonucleotide sequences each comprise about 5-15 bases, wherein said first and said second oligonucleotide sequences each comprise a complementary binding sequence of about 4-8 bases in length which is complementary to the bridging oligonucleotide sequence, and wherein said one or more bridging oligonucleotides comprise about 5-20 bases.

31. The kit of claim 1 , wherein a binding energy between said bridging oligonucleotide sequence and said complementary portion of said first oligonucleotide sequence and said complementary portion of said second oligonucleotide sequence is below a level to stably attach said bridging oligonucleotide sequence to both of said first oligonucleotide sequence and said second oligonucleotide sequence in the absence of simultaneous binding of said first and second binding regions to said analyte.

32. The kit of claim 2 , wherein a binding energy between said bridging oligonucleotide sequence and said complementary portion of said first oligonucleotide sequence and said complementary portion of said second oligonucleotide sequence is below a level to stably attach said bridging oligonucleotide sequence to both of said first oligonucleotide sequence and said second oligonucleotide sequence in the absence of simultaneous binding of said first and second binding regions to said analyte.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2021
From: GLEZER, ELI N.; SIGAL, GEORGE
To: MESO SCALE TECHNOLOGIES, LLC.
Reel/Frame 057834/0331 →
Continuity (4)
Division 15696953 · Sep 6, 2017
Division 14357653
Provisional Application 61558537 · Nov 11, 2011
Related Publication 20220033918A1 · Feb 3, 2022
References Cited (80)
US 5093268A · Leventis et al. · 1992 [cited by applicant]
US 5147806A · Kamin et al. · 1992 [cited by applicant]
US 5200314A · Urdea · 1993 [cited by applicant]
US 5238808A · Bard et al. · 1993 [cited by applicant]
US 5240863A · Shibue et al. · 1993 [cited by applicant]
US 5308754A · Kankare et al. · 1994 [cited by applicant]
US 5324457A · Zhang et al. · 1994 [cited by applicant]
US 5589136A · Northrup et al. · 1996 [cited by applicant]
US 5591581A · Massey et al. · 1997 [cited by applicant]
US 5597910A · Gudibande et al. · 1997 [cited by applicant]
US 5641623A · Martin · 1997 [cited by applicant]
US 5643713A · Liang et al. · 1997 [cited by applicant]
US 5679519A · Oprandy · 1997 [cited by applicant]
US 5705402A · Leland et al. · 1998 [cited by applicant]
US 5731147A · Bard et al. · 1998 [cited by applicant]
US 5776672A · Hashimoto et al. · 1998 [cited by applicant]
US 5786141A · Bard et al. · 1998 [cited by applicant]
US 5846485A · Leland et al. · 1998 [cited by applicant]
US 5866434A · Massey et al. · 1999 [cited by applicant]
US 6048687A · Kenten · 2000 [cited by examiner]
US 6066448A · Wohlstadter et al. · 2000 [cited by applicant]
US 6136268A · Ala-Kleme et al. · 2000 [cited by applicant]
US 6207369B1 · Wohlstadter et al. · 2001 [cited by applicant]
US 6214552B1 · Heroux et al. · 2001 [cited by applicant]
US 6673533B1 · Wohlstadter et al. · 2004 [cited by applicant]
US 6709815B1 · Dong et al. · 2004 [cited by applicant]
US 6939720B2 · Chandler et al. · 2005 [cited by applicant]
US 9714937B2 · Dunaway · 2017 [cited by examiner]
US 9777338B2 · Glezer et al. · 2017 [cited by applicant]
US 20010023063A1 · Richter · 2001 [cited by examiner]
US 20030077670A1 · Cheng · 2003 [cited by examiner]
US 20040121382A1 · Liu et al. · 2004 [cited by applicant]
US 20040142323A1 · Caine Boyde · 2004 [cited by applicant]
US 20040209261A1 · Keys et al. · 2004 [cited by applicant]
US 20040248103A1 · Feaver et al. · 2004 [cited by applicant]
US 20050003432A1 · Hall et al. · 2005 [cited by applicant]
US 20080188638A1 · Breitenkamp · 2008 [cited by examiner]
US 20090176318A1 · Kolpashchikov · 2009 [cited by applicant]
US 20090203155A1 · Chiku · 2009 [cited by examiner]
US 20100261292A1 · Glezer et al. · 2010 [cited by applicant]
US 20130059741A1 · Weiner · 2013 [cited by applicant]
US 20140315189A1 · Glezer et al. · 2014 [cited by applicant]
JP 2006511807A · 2006 [cited by applicant]
JP 2007525661A · 2007 [cited by applicant]
WO 9736931A1 · 1997 [cited by applicant]
WO 9812539A1 · 1998 [cited by applicant]
WO 9857154A1 · 1998 [cited by applicant]
WO 9914599A1 · 1999 [cited by applicant]
WO 9932662A1 · 1999 [cited by applicant]
WO 9958962A1 · 1999 [cited by applicant]
WO 9963347A2 · 1999 [cited by applicant]
WO 0003233A1 · 2000 [cited by applicant]
WO 2004061131A1 · 2004 [cited by applicant]
WO 2005059509A2 · 2005 [cited by applicant]
WO 2009067009A1 · 2009 [cited by applicant]
WO 2010059820A1 · 2010 [cited by applicant]
WO 2011047087A2 · 2011 [cited by applicant]
Chan D.W., “Immunoassay A Practical Guide”, Chapter 1, 7 pages I(1987). [cited by applicant]
Darmanis S. et al., “ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing”, PLOS One 6(9):e25583 (Sep. 29, 2011). [cited by applicant]
Fredriksson S. et al., “Protein Detection Using Proximity-Dependent DNA Ligation Assays”, Nature Biotechnology 20:473-477 (May 1, 2002). [cited by applicant]
Heyduk E. et al., “Molecular Pincers: Antibody-Based Homogeneous Protein Sensors”, Analytical Chemistry 80 (13):5152-5159 (Jul. 1, 2008). [cited by applicant]
Hochman J. et al., “An Active Antibody Fragment (Fv) Composed of the Variable Portions of Heavy and Light Chains”, Biochemistry 12(6):1130-1135 (1973). [cited by applicant]
Hu J. et al., “Quantitation of Femtomolar Protein Levels via Direct Readout With the Electrochemical Proximity Assay”, Journal of the American Chemical Society 134(16):7066-7072 (Mar. 27, 2012). [cited by applicant]
Porter R.R. et al., “Subunits of Immunoglobulins and Their Relationship to Antibody Specificity”, J. Cell Physiol. 67:Sup. 1:51-64 (1966). [cited by applicant]
Söderberg O. et al., “Characterizing Proteins and Their Interactions in Cells and Tissues Using the In Situ Proximity Ligation Assay”, Methods 45(3):227-232 (Jul. 1, 2008). [cited by applicant]
Tavoosidana G. et al., “Multiple Recognition Assay Reveals Prostasomes as Promising Plasma Biomarkers for Prostate Cancer”, PNAS 108(21):8809-8814 (May 24, 2011). [cited by applicant]
Weibrecht I. et al., “Proximity Ligation Assays: A Recent Addition to the Proteomics Toolbox”, Expert Reviews Proteomics 7(3):401-409 (2010). [cited by applicant]
International Search Report dated Mar. 15, 2013 received in PCT/US2012/064263. [cited by applicant]
European Office Action dated Jan. 27, 2020 received in European Application No. 18 192 525.6. [cited by applicant]
Extended European Search Report dated Jan. 7, 2019 received in European Patent Application No. 18 19 2525.6. [cited by applicant]
Japanese Office Action dated Mar. 16, 2021 received in Japanese Application No. 2020-079957, together with an English-language translation. [cited by applicant]
Japanese Decision of Rejection dated Jan. 7, 2020 received in Japanese Patent Application No. 2017-231321, together with an English-language translation. [cited by applicant]
Japanese Notice of Reasons for Rejection dated Aug. 16, 2016 received in Japanese Application No. 2014-541281, together with an English-language translation. [cited by applicant]
US Non-Final Office Action dated Mar. 9, 2021 received in U.S. Appl. No. 15/696,953. [cited by applicant]
US Final Office Action dated Jun. 15, 2020 received in U.S. Appl. No. 15/696,953. [cited by applicant]
US Final Office Action dated Nov. 25, 2019 received in U.S. Appl. No. 15/696,953. [cited by applicant]
US Non-Final Office Action dated Mar. 27, 2019 received in U.S. Appl. No. 15/696,953. [cited by applicant]
US Non-Final Office Action dated Jan. 31, 2017 received in U.S. Appl. No. 14/357,653. [cited by applicant]
US Final Office Action dated Jun. 22, 2016 received in U.S. Appl. No. 14/357,653. [cited by applicant]
US Non-Final Office Action dated Oct. 26, 2015 received in U.S. Appl. No. 14/357,653. [cited by applicant]
Cited By (2)
US 12,553,887 US 12,704,459